SCHEMBL5266423

SCHEMBL5266423

Cc1ccc(-c2c(-c3ccc(SC(C)C)c(Cl)c3)nc3ncccn23)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.45
PIM1 P11309 2/20 0.45
GSK3B P49841 2/20 0.45
GAA P10253 9/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GLA P06280 1/20 0.41
AKT1 P31749 2/20 0.40
AKT2 P31751 2/20 0.40
MAPT P10636 5/20 0.39
MAPK1 P28482 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
CDC7 O00311 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261473 0.96 GAA (0.44) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5261602 0.90 MAPT (0.45) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5262188 0.86 MAPT (0.47) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5261022 0.85 ALDH1A1 (0.53) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5261934 0.84 ROCK2 (0.44) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5263057 0.81 MAPK14 (0.43) KDM4ERAB9AAKT1AKT2MAPT
SCHEMBL5264684 0.80 GAA (0.42) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5263379 0.77 AKT1 (0.39) AKT1AKT2MAPTMAPK13MAPK12
SCHEMBL5259265 0.76 GAA (0.56) ROCK2PIM1GSK3BGAAALDH1A1
SCHEMBL5261650 0.76 ROCK2 (0.46) ROCK2PIM1GSK3BGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660500-B1 SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER S A L V A T LAB SA (ES) 2007-12-12 EP disclosed
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer BRCA1, CCNA1, DPYD ROCK2 4845/4885PIM1 1850/4885GSK3B 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.